SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-306290
Filing Date
2019-12-04
Accepted
2019-12-04 17:09:39
Documents
15
Period of Report
2019-12-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d843333d8k.htm   iXBRL 8-K 34704
2 EX-1.1 d843333dex11.htm EX-1.1 157481
3 EX-5.1 d843333dex51.htm EX-5.1 8411
7 GRAPHIC g843333dsp44.jpg GRAPHIC 3827
  Complete submission text file 0001193125-19-306290.txt   376947

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20191204.xsd EX-101.SCH 3067
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20191204_lab.xml EX-101.LAB 18139
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20191204_pre.xml EX-101.PRE 11406
11 EXTRACTED XBRL INSTANCE DOCUMENT d843333d8k_htm.xml XML 3443
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 191268797
SIC: 2834 Pharmaceutical Preparations